The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Discovery of a Keap1-dependent peptide PROTAC to knockdown Tau by ubiquitination-proteasome degradation pathway
Abstract
Induced protein degradation by PROTACs has emerged as a promising strategy to target nonenzymatic proteins inside the cell. The aim of this study was to identify Keap1, a substrate adaptor protein for ubiquitin E3 ligase involved in oxidative stress regulation, as a novel candidate for PROTACs that can be applied in the degradation of the nonenzymatic protein Tau. A peptide PROTAC by recruiting Keap1-Cul3 ubiquitin E3 ligase was developed and applied in the degradation of intracellular Tau. Peptide 1 showed strong in vitro binding with Keap1 and Tau. With proper cell permeability, peptide 1 was found to colocalize with cellular Keap1 and resulted in the coimmunoprecipitation of Tau and Keap1. The results of flow cytometry and western blotting assays showed that peptide 1 can downregulate the intracellular Tau level in both time- and concentration-dependent manner. The application of Keap1 siRNA silencing and the proteasome inhibitor MG132 confirmed that peptide 1 could promote the Keap1-dependent poly-ubiquitination and proteasome-dependent degradation of Tau. The results suggested that using PROTACs to recruit Keap1 to induce the degradation of Tau may show promising character in the treatment of neurodegenerative disease. Besides, our research demonstrated that Keap1 should be a promising E3 ligase adaptor to be used in the design of novel PROTACs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Importantly, induced turnover of tau by the UPS, and the degradability of tau species, has been demonstrated by a tau–kelch-like ECH-associated protein 1 (KEAP1) chimeric peptide PROTAC molecule188, as well as by a VHL–tau PROTAC189.”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [188]
In the citing paper
“Additionally, multiple groups have described a range of pepTACs that harness SKP1/SCF F-box, VHL, KEAP1 and other E3 ligases to degrade tau or α-synuclein in primary neurons and other cell lines188,193,213”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [188]
In the citing paper
“A peptide-based PROTAC which recruits the KEAP1 E3 ligase to degrade Tau protein demonstrates the potential of PROTAC technology to treat neurodegenerative disorders such as Alzheimer’s disease [73].”
From PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics (2020) · cites this paper as [73]
In the citing paper
“This PROTAC, termed peptide 1, was able to degrade overexpressed GFP-tagged Tau in different cell lines at 20 µM after 6–12 h of treatment times to various degrees.”
From Advances in targeted degradation of endogenous proteins (2019) · cites this paper as [105]
In the citing paper
“Recently, a peptide PROTAC was developed that was able to tether Kelch-like ECH-associated protein-1 (Keap1) and Tau into a ternary complex [105].”
From Advances in targeted degradation of endogenous proteins (2019) · cites this paper as [105]
In the citing paper
“Generation of the full-length peptide decreased Keap1 affinity tenfold and exhibited affinity towards Tau in the sub-micromolar range.”
From Advances in targeted degradation of endogenous proteins (2019) · cites this paper as [105]
In the citing paper
“Proof of concept for hijacking the BTB E3 ligases has been provided by a peptide PROTAC targeting Tau for degradation by KEAP1 (ref. 79 ).”
From Targeted protein degradation: expanding the toolbox (2019) · cites this paper as [79]
Citations
Cites
Sakamoto, K. M., Kim, K. B., Kumagai, A., Mercurio, F., Crews, C. M., & Deshaies, R. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141230798 · Cited by 2,609
Classification of Intrinsically Disordered Regions and Proteins
van der Lee, R., Buljan, M., Lang, B., Weatheritt, R. J., Daughdrill, G. W., Dunker, A. K., Fuxreiter, M., Gough, J., Gsponer, J., Jones, D. T., et al. (2014) · Chemical Reviews · doi:10.1021/cr400525m · Cited by 2,249
Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders
Ballatore, C., Lee, V. M.-Y., & Trojanowski, J. Q. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2194 · Cited by 2,174
Phthalimide conjugation as a strategy for in vivo target protein degradation
Winter, G. E., Buckley, D. L., Paulk, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., & Bradner, J. E. (2015) · Science · doi:10.1126/science.aab1433 · Cited by 1,760
Induced protein degradation: an emerging drug discovery paradigm
Lai, A. C., & Crews, C. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.211 · Cited by 1,486
Catalytic in vivo protein knockdown by small-molecule PROTACs
Bondeson, D. P., Mares, A., Smith, I. E. D., Ko, E., Campos, S., Miah, A. H., Mulholland, K. E., Routly, N., Buckley, D. L., Gustafson, J. L., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1858 · Cited by 1,356
Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
Lu, J., Qian, Y., Altieri, M., Dong, H., Wang, J., Raina, K., Hines, J., Winkler, J. D., Crew, A. P., Coleman, K., et al. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2015.05.009 · Cited by 1,140
Hoover, B. R., Reed, M. N., Su, J., Penrod, R. D., Kotilinek, L. A., Grant, M. K., Pitstick, R., Carlson, G. A., Lanier, L. M., Yuan, L.-L., et al. (2010) · Neuron · doi:10.1016/j.neuron.2010.11.030 · Cited by 1,118
Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4
Zengerle, M., Chan, K.-H., & Ciulli, A. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00216 · Cited by 1,056
The Keap1–Nrf2–ARE Pathway As a Potential Preventive and Therapeutic Target: An Update
Lu, M., Ji, J., Jiang, Z., & You, Q. (2016) · Medicinal Research Reviews · doi:10.1002/med.21396 · Cited by 815
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- Lu, 2016, The Keap1–Nrf2–ARE pathway as a potential preventive and therapeutic target: an update, Med. Res. Rev., 36, 924, 10.1002/med.21396 · DOI
Cited by
Sorted by citations
Items 201–300 of 321
Bifunctional robots inducing targeted protein degradation
Sobhia, M. E., Kumar, H., & Kumari, S. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115384 · Cited by 11
Hymel, H. C., Anderson, J. C., Liu, D., Gauthier, T. J., & Melvin, A. T. (2023) · Biochemical Engineering Journal · doi:10.1016/j.bej.2023.109063 · Cited by 11
Wang, Y., Deng, S., & Xu, J. (2020) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0066 · Cited by 10
Recent Advancements in Strategies for Abnormal Protein Clearance in Alzheimer's Disease
Zhuang, J., Gao, J., Yin, Y., Gong, B., Ji, W., Chen, X., Li, P., Cheng, W., Zhao, Y., & He, B. (2022) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557522666220214092824 · Cited by 10
Khramtsov, Y. V., Ulasov, A. V., Lupanova, T. N., Slastnikova, T. A., Rosenkranz, A. A., Bunin, E. S., Georgiev, G. P., & Sobolev, A. S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics16010004 · Cited by 8
Vaithiyanathan, M., Hymel, H. C., Safa, N., Sanchez, O. M., Pettigrew, J. H., Kirkpatrick, C. S., Gauthier, T. J., & Melvin, A. T. (2020) · AIChE Journal · doi:10.1002/aic.17087 · Cited by 9
Diverse influences on tau aggregation and implications for disease progressionPreprint
Alstyne, M. V., Pratt, J., & Parker, R. (2025) · Genes & Development · doi:10.1101/gad.352551.124 · Cited by 11
Promising Proteolysis-Targeting Chimera for Mutant p53-R175H
Zhuang, X., Guo, Y., Sun, X., Chen, J., Xie, S., Yang, F., & Li, J. (2024) · ACS Omega · doi:10.1021/acsomega.4c06177 · Cited by 8
Jia, S., Li, Q., Rui, X., Qin, W., Zhang, W., Dou, J., & Zhang, X. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1730206 · Cited by 8
PROTAC: A Novel Drug Delivery Technology for Targeting Proteins in Cancer Cells
Bala, R., Sindhu, R. K., Madaan, R., & Yadav, S. K. (2022) · Current Drug Discovery Technologies · doi:10.2174/1570163820666221031124612 · Cited by 8
PROTAC technology for prostate cancer treatment
Wang, Z., Zhang, D., Inuzuka, H., & Wei, W. (2025) · Acta Materia Medica · doi:10.15212/amm-2024-0075 · Cited by 9
Tomoshige, S., & Ishikawa, M. (2020) · Angewandte Chemie · doi:10.1002/ange.202004746 · Cited by 8
Ciulli, A., & Hsia, O. (2022) · Wiley eBooks · doi:10.1002/9781119774198.ch9 · Cited by 8
Li, X., Ba, Z., Huang, J., Chen, J., Jiang, J., Huang, N., & Luo, Y. (2024) · Ibrain · doi:10.1002/ibra.12176 · Cited by 7
Chemical knockdown of Keap1 and homoPROTAC-ing allergic rhinitis
Yan, J., Wang, T., Yu, R., Xu, L., Shao, H., Li, T., Wang, Z., Cha, X., Miao, Z., Xing, C., et al. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.05.025 · Cited by 7
Olazábal-Morán, M., Pérez, E., Esteban-Arranz, A., & Garrido, A. (2025) · Biomolecules · doi:10.3390/biom15091316 · Cited by 7
Engineering brain-penetrant PROTACs: Bridging molecular design and CNS delivery
Li, X., Li, J., Sun, Y., Yao, T., Lu, Y., Liu, S., Li, H., Shi, Y., Chen, L., Zhao, Y., et al. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115876 · Cited by 8
Zhang, S.-H., Zeng, N., Xu, J., Liu, C., Xu, M., Sun, J., An, Y., Zhong, X., Miao, L.-T., Wang, S., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117584 · Cited by 9
Major Advances in Emerging Degrader Technologies
Luo, H., Wu, L., He, Y., Qin, C., & Tang, X. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.921958 · Cited by 7
N-Heterocycle based Degraders (PROTACs) Manifesting Anticancer Efficacy: Recent Advances
Banerjee, S., Sharma, S., Thakur, A., Sachdeva, R., Sharma, R., Nepali, K., & Liou, J. (2023) · Current Drug Targets · doi:10.2174/0113894501273969231102095615 · Cited by 7
Design and Applications of Bifunctional Small Molecules in Biology
Boyd, S. R., Chang, L., de Rezende, W. C., Raji, I. O., Kandel, P., Holmes, S. L., & Young, D. W. (2020) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2020.140534 · Cited by 7
Synthetic Protein Circuits and Devices Based on Reversible Protein-Protein Interactions: An Overview
Rosa, S., Bertaso, C., Pesaresi, P., Masiero, S., & Tagliani, A. (2021) · Life · doi:10.3390/life11111171 · Cited by 8
Exploring DCAF15 for reprogrammable targeted protein degradationPreprint
Coomar, S., & Gillingham, D. G. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/542506 · Cited by 7
From Degraders to Molecular Glues: New Ways of Breaking Down Disease‐Associated Proteins
Nagel, Y. A., Britschgi, A., & Ricci, A. (2021) · Wiley eBooks · doi:10.1002/9783527826872.ch2 · Cited by 6
Targeted Degradation of Protein Kinase A via a Stapled Peptide PROTAC
Whittaker, M. K., Bendzunas, G. N., Shirani, M., LeClair, T. J., Shebl, B., Dill, T. C., Coffino, P., Simon, S. M., & Kennedy, E. J. (2024) · ACS Chemical Biology · doi:10.1021/acschembio.4c00237 · Cited by 6
PROTAC-mediated Target Degradation: A Paradigm Changer in Drug Discovery?
Cromm, P. M., Crews, C. M., & Weinmann, H. (2020) · Royal Society of Chemistry eBooks · doi:10.1039/9781839160691-00001 · Cited by 6
Verbič, A., Lebar, T., Praznik, A., & Jerala, R. (2024) · ACS Synthetic Biology · doi:10.1021/acssynbio.3c00588 · Cited by 6
Protein Phosphatase 5-Recruiting Chimeras for Accelerating Tau Dephosphorylation
Gu, J., He, C., Han, Z., Huang, Q., He, Y., Lu, Y., You, Q., Zhang, Q., & Wang, L. (2025) · ACS Chemical Biology · doi:10.1021/acschembio.5c00165 · Cited by 5
Self-citationAdvances in Alzheimer’s disease: mechanistic insights and therapeutic targets
Jia, Y.-J., Ge, Y., Li, B., Yang, Y., Chen, H., Liu, J., Guo, J., Yu, J., Ye, K., Wang, J., et al. (2026) · Science China Life Sciences · doi:10.1007/s11427-025-2991-7 · Cited by 6
Heterobifunctional proteomimetic polymers for targeted degradation of MYC and KRAS
Wang, M. M., Truica, M. I., Gattis, B. S., Oktawiec, J., Sagar, V., Basu, A. A., Bertin, P. A., Zhang, X., Abdulkadir, S. A., & Gianneschi, N. C. (2026) · Nature Communications · doi:10.1038/s41467-026-68913-3 · Cited by 7
Ozleyen, A., Kulabas, S. S., Novak, M. J., Cichoń, M., Heras, C. M. D. L., Honda, T., Doveston, R. G., Dinkova‐Kostova, A. T., Grochot‐Przeczek, A., & Tumer, T. B. (2026) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2026.110847 · Cited by 5
Emerging Novel Therapeutic Approaches for the Treatment of Alzheimer’s Disease
Panwar, A., Khan, M. I. K., Kumar, R., Kumar, R., Kumar, S., & Kumar, A. (2024) · Advances in Alzheimer s Disease · doi:10.4236/aad.2024.133006 · Cited by 5
Wang, Y., He, Y., You, Q., & Wang, L. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104194 · Cited by 5
Self-citationPROTACs in targeted protein degradation: Advances in development and AI-enhanced drug discovery
Du, M., Liu, T., Wang, W., Fan, S., Tian, M., Du, Q., Wang, Z., Li, X., Liu, X., Xia, Q., et al. (2026) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2026.100332 · Cited by 4
Self-citationMechanisms and Design Principles of Proteolysis-Targeting Chimeras and Their Emerging Applications
Knoll, N., Neamati, N., & Üren, A. (2026) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00730 · Cited by 5
Targeted tau protein degradation: a promising therapeutic approach for tauopathies
Baazaoui, N., Alfaifi, M. Y., Shati, A. A., Saad, R. B., & Garzoli, S. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.11.041 · Cited by 5
A pharmacological modality to sequester homomeric proteins
Livnah, E., Suss, O., Rogel, A., Gilat, A., Abdan, Y., Villegas, J. A., Gabizon, R., Nadir, A., Shamir, Y., Steinman, N. Y., et al. (2026) · Nature Chemical Biology · doi:10.1038/s41589-026-02141-0 · Cited by 4
Aptamer and N-Degron Ensemble (AptaGron) as a Target Protein Degradation Strategy
Mazid, M. F. A., Shkel, O., Ryu, E., Kim, J., Shin, K. H., Kim, Y. K., Lim, H., & Lee, J. (2024) · ACS Chemical Biology · doi:10.1021/acschembio.4c00536 · Cited by 4
Riching, K. M., Mahan, S. D., Urh, M., & Daniels, D. L. (2020) · Journal of Visualized Experiments · doi:10.3791/61787-v · Cited by 4
PROTACs for central nervous system disorders: challenges and opportunities
Zheng, N., Shao, J., Xiong, B., Wei, Y., Wang, X., Zhou, Y., Song, Z., Zhang, A., Xu, C., Zhao, Q., et al. (2026) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2026.118703 · Cited by 4
George, N., Akhtar, M. J., Balushi, K. A. A., Safi, S. Z., Azmi, S. N. H., & Khan, S. A. (2023) · Medicinal Chemistry Research · doi:10.1007/s00044-023-03026-w · Cited by 3
DNA Nanotechnology for Application in Targeted Protein Degradation
Xiao, Y., Guo, X., Zhang, W., Ma, L., & Ren, K. (2024) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.4c01351 · Cited by 4
Advancing brain tumor therapy: unveiling the potential of PROTACs for targeted protein degradation
Ibrahim, S., Khan, M. U., Noreen, S., Firdous, S., Khurram, I., Rehman, R., Javed, M. A., & Ali, Q. (2025) · Cytotechnology · doi:10.1007/s10616-025-00716-8 · Cited by 3
Proteolysis-Targeting Chimeras: A Kaleidoscope of Targeted Protein Degradation
Mou, Y., Wen, S., Gao, X., & Jiang, Z. (2021) · Future Medicinal Chemistry · doi:10.4155/fmc-2021-0199 · Cited by 3
Self-citationNanoparticle-mediated delivery of peptide-based degraders enables targeted protein degradationPreprint
Ghosal, S., Robertus, C. M., Wang, J., Chan, H. W., Alamgir, A., Almonte, J., & Alabi, C. A. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.17.584721 · Cited by 5
Cairang, N., Wu, Y., Zhi, S., Tang, J., Tie, X., Zhan, D., Lu, G., Shi, Y., & Zhao, Q. (2025) · RSC Advances · doi:10.1039/d4ra06512c · Cited by 2
Pharmacological mechanism and structure of ubiquitin proteases associated with depression: A review.
Jiang, Y., Ye, L., Han, K.-X., Bao, L., Zhao, F., Wang, D., Li, X., Sun, Z.-M., & Chen, J. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.145220 · Cited by 2
Post‐Covid Alzheimer and Its Remediation via PROTACs Therapy: A Comprehensive Review
Bhowmick, T., Basu, R., Mitra, A. K., Ali, S. A., Kumer, A., & Dhara, B. (2025) · Health Science Reports · doi:10.1002/hsr2.71631 · Cited by 2
Leveraging peptides for targeted protein degradation
Li, Y., Wang, X., Wang, X., Zhang, R.-S., Zhang, Z. D., Cao, X. W., Li, J. R., & Yang, L. (2026) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgag076 · Cited by 2
Khramtsov, Y. V., Ulasov, A. V., Lupanova, T. N., Georgiev, G. P., & Sobolev, A. S. (2023) · Doklady Biochemistry and Biophysics · doi:10.1134/s1607672923700710 · Cited by 2
Khramtsov, Y. V., Ulasov, A. V., Lupanova, T. N., Georgiev, G. P., & Sobolev, A. S. (2023) · Doklady Biochemistry and Biophysics · doi:10.1134/s1607672923700709 · Cited by 2
Tang, J., Tie, X., Zhi, S., Wang, Z., Zhao, Q., Qu, Z., Lu, G., Li, Q., Wu, Y., & Shi, Y. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107741 · Cited by 2
Boosting Brain Clean-Up: Can Targeting UPS Genes Offer Neuroprotection?
Mannan, A., Sharma, A., & Singh, T. G. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05263-z · Cited by 2
Protac: redirecting protein degradation systems to new substrates
Esperón, Á. C., & Villacampa, M. (2022) · Anales de la Real Academia Nacional de Farmacia · doi:10.53519/analesranf.2022.88.01.03 · Cited by 1
Targeted Protein Degradation: "The Gold Rush is On!"
Kotlarek, D., Pawlik, A., Sagan, M., Sowała, M., Zawiślak-Architek, A., & Walczak, M. (2020) · Technology Transfer and Entrepreneurship · doi:10.2174/2213809907666200130111436 · Cited by 2
Application of PROTAC Technology in Drug Development
Kharkar, P. S., & Jadhav, A. L. (2022) · Methods and principles in medicinal chemistry · doi:10.1002/9783527827855.ch10 · Cited by 2
Insights and Future Perspectives of Covalent Protein Degraders
Zhang, X. (2022) · Wiley eBooks · doi:10.1002/9783527836208.ch8 · Cited by 2
Targeted Protein Degradation as a Therapeutic Strategy in Neurodegenerative Diseases
Ferguson, F. M. (2022) · Wiley eBooks · doi:10.1002/9783527836208.ch7 · Cited by 2
NRDN: A novel nuclear degradation tag for targeted protein regulation in Arabidopsis
Shen, L., Huang, H., Yan, D., Ye, Y., & Hu, J. (2025) · Plant Science · doi:10.1016/j.plantsci.2025.112529 · Cited by 1
Singh, S., Saini, V., Shevtsov, M., & Jha, H. C. (2025) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2025.11.005 · Cited by 1
Broadening the horizon: The promise of PROTACs in non-malignant disorders
Fu, L., Zeng, G., Cao, Y., He, Y., Zhao, Y., Tian, C., Chen, J., Feng, H., Xi, J., Shao, J., et al. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118586 · Cited by 1
Wang, B., Li, Y., Yao, T., Shen, X., Li, H., Jiang, W., Li, X., & Zhu, Z. (2026) · RSC Medicinal Chemistry · doi:10.1039/d5md00963d · Cited by 2
Contemporary Developments in PROTACs for Cancer Management: An In-Depth Review
Rahaman, S. A., Venkateswarlu, G., Patel, S., Mishra, P. S., Kumar, R., & Parvez, N. (2026) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266384226251013054011 · Cited by 1
Monoclonal antibodies and small molecules: on the cutting edge of Alzheimer’s disease therapy
Ouro, A., Ben-Dor, G. A., Debasa‐Mouce, M., Gulkarov, S., Leon, J. D., Castro‐Mosquera, M., Sobrino, T., Bougea, A. M., & Reiss, A. B. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1766762 · Cited by 1
Jiang, Y., Tetlow, A. M., Lin, Y., Ji, C., Ader, J., Laborc, K. F., Mar, A. C., Pan, R., Kong, X., Congdon, E. E., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.aea4205 · Cited by 2
Redirecting TRIM21 with TRIMTACs for the targeted degradation of multimeric proteins
de Gialluly, M. A. S., & Adams, D. (2026) · FEBS Journal · doi:10.1111/febs.70548 · Cited by 1
E3 ubiquitin ligases in neurodegenerative diseases
Hou, D. L., Ho, J., Guan, T., Dong, X.-X., Zeng, L., Sanders, L. H., Wu, Y., Tan, E., & Zhou, Z. D. (2026) · Military Medical Research · doi:10.1016/j.mmr.2026.100032 · Cited by 1
Ma, C.-C., Jin, C., Guo, N.-J., Liu, H. F., Yin, Q.-G., Wang, Y., Liu, Y.-F., Zhang, Y., Wang, N., Lu, G., et al. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.110067 · Cited by 1
Self-citationBellver‐Sanchís, A., Ralchev, N., Romanska, P. R., Dyakova, N. K., Ivanova, K. I., Griñán‐Ferré, C., & Marchev, A. S. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177833 · Cited by 1
Targeted Protein Degradation Chemical Probes
Galdeano, C., & Barril, X. (2020) · Royal Society of Chemistry eBooks · doi:10.1039/9781839160745-00150 · Cited by 1
Novel Technologies in PROTAC Design
Jain, K., Reddy, S. C., Moode, S., Mehra, P., Tarannum, S., Patel, M., Jain, V. K., & Popli, H. (2024) · Springer eBooks · doi:10.1007/978-981-97-5077-1_5 · Cited by 1
Wang, S., Jiang, S., Zheng, G., & Cho, Y. K. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.01.506229 · Cited by 2
WITHDRAWN: Targeted protein degradation: A promising approach for cancer treatment
Khan, M. Z. I., Nazli, A., Naz, I., Khan, D., Haq, I., & Chen, J. (2023) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2023.09.004 · Cited by 1
RetractedNanoparticle-mediated delivery of peptide-based degraders enables targeted protein degradationPreprint
Alabi, C. A., Ghosal, S., Robertus, C. M., Wang, J., Chan, H., Alamgir, A., & Almonte, J. (2024) · Research Square · doi:10.21203/rs.3.rs-3797623/v1 · Cited by 1
Jiang, Y., Tetlow, A. M., Lin, Y., Ji, C., Laborc, K. F., Mar, A. C., Pan, R., Kong, X., Congdon, E. E., & Sigurdsson, E. M. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.30.662446 · Cited by 1
Idegenerering i IT-bedrifter - åpenhet og nettverks betydning for idégenerering
Liafjell, T. A. (2014) · NORA - Norwegian Open Research Archives
Lowe, J. A., III (2021) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.739908982.793584562
Li, Z., Zhao, H., & Wan, C. (2021) · Wiley eBooks · doi:10.1002/9783527343430.ch6
Development of a Peptide-based PROTAC Incorporating a �-hairpin Sequence
Hymel, H. C. (2022) · Louisiana State University · doi:10.31390/gradschool_dissertations.6043
New Therapeutic Chemical Modalities: Compositions, Modes-of-action, and Drug Discovery
Valeur, E. (2023) · Royal Society of Chemistry eBooks · doi:10.1039/9781788018982-00911
Khramtsov, Y. V., Ulasov, A. V., Lupanova, T. N., Georgiev, G. P., & Sobolev, A. S. (2024) · Доклады Российской академии наук Науки о жизни · doi:10.31857/s2686738924020085
Khramtsov, Y. V., Ulasova, A. V., Lupanova, T. N., Georgiev, G. P., & Sobolev, A. S. (2024) · Доклады Российской академии наук Науки о жизни · doi:10.31857/s2686738924020053
Xia, J., Norris, J. K. S., Mackinnon, M., & Butterworth, S. (2024) · International Journal of Drug Discovery and Pharmacology · doi:10.53941/ijddp.2024.100015 · Cited by 1
Longhini, A. P., Fattah, M. A., Sala‐Jarque, J., DuBose, A., Rivera, E. K., Sclafani, O., Zhou, J., Anatot, J. E., Thompson, M. P., Unger, M. T., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.02.636155 · Cited by 1
Heterobifunctional proteomimetic polymers for targeted protein degradationPreprint
Wang, M. M., Truica, M. I., Gattis, B. S., Oktawiec, J., Sagar, V., Basu, A. A., Bertin, P. A., Zhang, X., Abdulkadir, S. A., & Gianneschi, N. C. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.07.641543
Yadav, S. K., Maurya, M. K., Tyagi, C., Rai, R., Bhat, B., & Das, M. (2025) · Springer eBooks · doi:10.1007/978-981-96-6202-9_4
Inducers of Targeted Protein Degradation as Drug Candidates for Neurodegenerative Disorders
Tomoshige, S., & Ishikawa, M. (2025) · Wiley eBooks · doi:10.1002/9783527844678.ch11
Structural biology and computer-aided drug design
Singh, P., Hassan, S., Mehdi, M. M., Kumar, V. R., & Biswas, K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27461-9.00008-1
Targeted degradation of pathologic tau aggregates via AUTOTAC ameliorates tauopathyPreprint
Lee, J., Kim, S., Kim, H. Y., Lee, G. E., Lee, D. W., Jung, E. H., Lee, J. S., Cho, E. H., Park, H., Park, D.-H., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.10.675324
Tewari, A., Pawar, A. B., & Roy, S. (2026) · In Silico Research in Biomedicine · doi:10.1016/j.insi.2026.100372 · Cited by 1
Wang, R., Maloney, B., Nho, K. T., Beck, J. S., Counts, S., & Lahiri, D. K. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.11.731747
Programmable Nanobody‐Targeting Chimeras Enable Intracellular Viral Protein Degradation
Pan, M. Y.-C., Lee, T.-H., Peng, T., Wu, E. Y.-H., Chiu, Y., Chiu, C.-C., Nguyễn, H. V., Pao, Y.-S., Chao, M., Lee, R. K., et al. (2026) · Advanced Science · doi:10.1002/advs.76687
Sprayable androgen receptor PROTAC degrader for immunomodulation and accelerated skin regeneration
Jang, S. Y., Park, B., Ko, E., 신동원, Jang, Y., Lee, W. S., Lee, J.-H., Lee, A., Park, J., Lee, S. P., et al. (2026) · Chemical Engineering Journal · doi:10.1016/j.cej.2026.179954
Ren, Z., Yue, Q., Gao, N., Hao, Q.-L., Huo, Y., Li, C., Leng, X., Sun, L., Hoi, M. P. M., Han, H., et al. (2026) · Advanced Science · doi:10.1002/advs.77545 · Cited by 1
Enzyme−Targeted Therapeutics for Neurological Disorders
Massignan, L., Lokesh, K., Ziadat, S., Uehling, D., Weaver, D. F., & Reed, M. A. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c01274
Recent advances in the development of tag-targeted protein degradation systems
Li, B., Lu, Y., Che, J., & Dong, X. (2026) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2026.2742479
BindingDB Entry 50017954: PROTACs to address the challenges facing small molecule inhibitors.
BindingDB (2023) · UC San Diego · doi:10.7270/q2p55sm1
Metadata
- Authors
- Lu, M., Liu, T., Jiao, Q., Ji, J., Tao, M., Liu, Y., You, Q., & Jiang, Z.
- Affiliations
- China Pharmaceutical University (CN)
- Corresponding author
- You, Qidong
- Jiang, Zhengyu
- Venue
- European Journal of Medicinal Chemistry
- Publisher
- Elsevier BV
- Published
- 2018-02
- Volume
- 146
- Pages
- 251-259
- ISSN
- 0223-5234 (ISSN-L)
- OpenAlex
- W2792069216
- Cited by
- 310
- References
- 45
- Citations by year
- 2026: 30 · 2025: 46 · 2024: 48 · 2023: 47 · 2022: 35 · 2021: 36 · 2020: 37 · 2019: 24 · 2018: 6
- FWCI
- 9.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (81773581, 81602948, 81773639)
- Natural Science Foundation of Jiangsu Province of China (BK20160746)
- National Major Science and Technology Project of China (2015ZX09101032, 2017ZX09302003, 2017ZX09101-004-003-006)
- Research Innovation Program for College Graduates of Jiangsu Province (KYLX16_1169)
- Priority Academic Program Development of Jiangsu Higher Education Institutions, the Project Program of State Key Laboratory of Natural Medicines, China Pharmaceutical University (SKLNMZZCX201611)
- College Students Innovation Project for the R&D of Novel Drugs (J1310032)
- China Postdoctoral Science Foundation funded project (1600010006)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Keywords
- PROTACs, Keap1, tau protein, ubiquitination, proteasomal degradation, protein degradation, neurodegenerative diseases, polyubiquitination
- MeSH terms
- Kelch-Like ECH-Associated Protein 1, Dose-Response Relationship, Drug, Humans, Peptides, Structure-Activity Relationship, Tumor Cells, Cultured, Molecular Structure, tau Proteins, Proteasome Endopeptidase Complex, Ubiquitination, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
